Informed Decision-Making in the Treatment and Management of MS: Optimizing Therapeutic Switching and Sequencing

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2020 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive

This activity is valid from May 1, 2020 to May 1, 2021

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Biogen, Celgene, Genentech, and Sanofi Genzyme

Description:
Multiple Sclerosis (MS) is a chronic progressive disease. It is the most common neurological cause of disability among young adults, with a prevalence of approximately 400,000 cases throughout the United States, and every week around 200 people are diagnosed with the disease. Although there is still no cure for MS, many advances in MS treatment have arrived in recent years, allowing patients to manage these symptoms and improve their quality of life. A number of factors must be considered when selecting a treatment regimen for patients with MS, including variations in clinical and MRI evidence of disease. Over the past decade, there have been numerous revisions to MS diagnostic criteria and the development of multiple new and emerging therapies. While the explosion of these emerging therapies have shown the ability to improve outcomes and quality of life in patient's relapsing MS, it makes staying current with best practices a challenge that must be overcome through education. New options showing improved efficacy, safety and deliverability are now here, especially for patients who have not responded to previous treatments.

Upon completion of this activity, participants will be able to:

  • Analyze the impact of multiple sclerosis (MS) on a patient's quality of life and the economic burden to the healthcare system

  • Explore the latest clinical data on the efficacy, safety, and dosing/administration of current and emerging MS therapies and their effect on staging and sequencing

  • Assess recently updated evidence-based data and strategies for the rationale of sequencing, switching, and/or escalating MS therapeutics

  • Integrate utilization management and benefit design strategies for MS therapies to enhance clinical and economic outcomes for patients with MS

  • Identify and overcome access, adherence, and site of care issues that hinder optimal MS treatment

  • Examine practices that managed care professionals can take to help improve outcomes, mitigate disease progression and ensure appropriate and timely access to disease-modifying therapies for MS
     

Faculty: Clyde Markowitz, MD
Associate Professor of Neurology
Director, Multiple Sclerosis Center
Hospital of the University of Pennsylvania
Perelman School of Medicine

Disclosure:

Dr. Markowitz serves as a consultant to Alexion, Actelion, Bayer, Celgene, EMD-Soreno, Genentech, Genzyme, Novartis, Sanofi, and Teva. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
Biogen, Celgene, Genentech, and Sanofi Genzyme

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue